Table 2.
Treatment Duration and Patient Disposition
| Sunitinib (N = 63) | |||
|---|---|---|---|
| Characteristic | No. of Patients |
% | |
| Weeks on treatment | |||
| Median | 11 | ||
| Range | 1–54 | ||
| Treatment interruption | 15 | 24 | |
| Adverse event | 14 | 22 | |
| Other | 2 | 3 | |
| Dose reduction | 14 | 22 | |
| Reductions to 37.5 mg | 11 | 17 | |
| Reductions to 25 mg | 3 | 5 | |
| Primary reason for treatment discontinuation | |||
| Disease progression | 41 | 65 | |
| Adverse events | 18* | 29 | |
| Consent withdrawn | 2 | 3 | |
| Patient completed study per protocol | 2 | 3 | |
*
Includes one patient for whom the adverse event was grade 5 disease progression.